Consolidative and salvage primary-tumour SABR showed similar outcomes in stage IV NSCLC
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.
Primary-tumour SABR before progression or at oligoprogression produced similar survival and pneumonitis rates in selected patients with stage IV NSCLC.
ATR inhibition increased radiation-induced cell killing and inflammatory signalling in KRAS wild-type pancreatic cancer cells, with weaker immunogenic effects in KRAS-mutated cells.
At equal physical dose, carbon ions produced transcriptional changes distinct from X-rays, including stronger suppression of mitotic and chromatin-regulatory programmes.
DCAF4 activated NRF2-dependent antioxidant defence and protected hepatocellular carcinoma against iodine-125 brachytherapy in preclinical models.
Quantitative T1 relaxation time distinguished complete from incomplete rectal cancer response six weeks after neoadjuvant treatment with an area under the curve of 0.94.
FLASH spared mitochondrial integrity in non-tumorigenic pancreatic models while producing tumour effects comparable with conventional-dose-rate irradiation.
A case report describes pathology-confirmed late radiation necrosis after stereotactic radiosurgery, with radiographic progression temporally associated with repeated COVID-19 vaccination.
Iodine-125 doses of 140–160 grays were associated with longer median survival than 120–140 grays in recurrent glioblastoma.
Smaller base-of-tongue volume was associated with prolonged feeding-tube dependence after radiotherapy for oral cavity squamous cell carcinoma.
Spine proton ablative radiotherapy achieved 74% local control at one and two years, with no radiation myelopathy in a reirradiation-enriched cohort.
MRI-guided SBRT with 2-mm margins reduced low- and intermediate-dose exposure of neurovascular bundles and pudendal arteries versus CT-guided treatment.
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
Lower pretreatment microvascular health was associated with more acute toxicity overall, while disease-specific performance was strongest in breast cancer.
In mice, FLASH reduced acute chemokine and later macrophage-associated transcription versus conventional irradiation, without significantly reducing collagen deposition.
Immuno-Eclipse radiotherapy improved bulky tumor control in mice through natural killer and cytotoxic T-cell immunity.